These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27654985)

  • 1. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
    Johansson S; Leonsson-Zachrisson M; Knutsson M; Spencer AG; Labonté ED; Deshpande D; Kohler J; Kozuka K; Charmot D; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):448-456. PubMed ID: 27654985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
    King AJ; Kohler J; Fung C; Jiang Z; Quach A; Kumaraswamy P; Chertow GM; Rosenbaum DP
    Am J Physiol Renal Physiol; 2021 Jan; 320(1):F133-F144. PubMed ID: 33283643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
    Johansson SA; Knutsson M; Leonsson-Zachrisson M; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):457-465. PubMed ID: 28339149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
    Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
    Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
    King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
    Johansson S; Rosenbaum DP; Ahlqvist M; Rollison H; Knutsson M; Stefansson B; Elebring M
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):466-475. PubMed ID: 28301096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.
    Rosenbaum DP; Yan A; Jacobs JW
    Clin Drug Investig; 2018 Apr; 38(4):341-351. PubMed ID: 29363027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenapanor administration and the activity of the H
    Johansson S; Rosenbaum DP; Palm J; Stefansson B; Knutsson M; Lisbon EA; Hilgendorf C
    Br J Clin Pharmacol; 2017 Sep; 83(9):2008-2014. PubMed ID: 28432691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
    Spencer AG; Labonte ED; Rosenbaum DP; Plato CF; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Bell N; Tabora J; Joly KM; Navre M; Jacobs JW; Charmot D
    Sci Transl Med; 2014 Mar; 6(227):227ra36. PubMed ID: 24622516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
    Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
    J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Stefansson BV; Rydén-Bergsten T; Greasley PJ; Johansson SA; Knutsson M; Carlsson BC
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1597-1605. PubMed ID: 27340281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.
    Nakayama M; Kobayashi S; Kusakabe M; Ohara M; Nakanishi K; Akizawa T; Fukagawa M
    Clin Exp Nephrol; 2024 Feb; 28(2):153-164. PubMed ID: 37910313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study.
    Silva A; Edelstein S; Yang Y; Rosenbaum D; Battelli L; Chertow GM
    Curr Med Res Opin; 2024 Aug; 40(8):1345-1356. PubMed ID: 39041778
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA; Rosenbaum DP; Yan A; Chertow GM
    J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
    Lin T; Al-Makki A; Shepler B
    J Pharm Pharm Sci; 2022; 25():77-83. PubMed ID: 35041802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
    Block GA; Bleyer AJ; Silva AL; Weiner DE; Lynn RI; Yang Y; Rosenbaum DP; Chertow GM
    Kidney360; 2021 Oct; 2(10):1600-1610. PubMed ID: 35372979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
    Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
    Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.